Baillie Gifford & CO Clovis Oncology, Inc. Put Options Transaction History
Baillie Gifford & CO
- $131 Billion
- Q3 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding CLVS
# of Institutions
1Shares Held
166Call Options Held
0Put Options Held
0About Clovis Oncology, Inc.
- Ticker CLVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 144,480,000
- Market Cap $13M
- Description
- Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...